F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
31 hedge funds and large institutions have $5.59M invested in F-star Therapeutics, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 11 closing their positions.
23% less funds holding
Funds holding: 40 → 31 (-9)
58% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 12
75% less capital invested
Capital invested by funds: $22.3M → $5.59M (-$16.7M)
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$162K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$36.9K |
| 3 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$32.1K |
| 4 |
BlackRock
New York
|
+$20K |
| 5 |
Morgan Stanley
New York
|
+$9.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.9M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$1.36M |
| 3 |
Axa
Paris,
France
|
-$1.3M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$952K |
| 5 |
PCM
Parsons Capital Management
Providence,
Rhode Island
|
-$577K |
FSTX Hedge Fund Activity: Q4 2019 in Review
31 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q4 2019, worth a combined $5.59M — down 75% from $22.3M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of FSTX and 2 opened new positions — a net loss of 9 holders — while 12 trimmed existing stakes and 5 added.
The largest buyer was Renaissance Technologies, adding an estimated $162K. The largest seller was Adage Capital Partners, exiting entirely with an estimated $4.9M sold.
- 31 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q4 2019, down from 40 in Q3 2019.
- Funds reported $5.59M of F-star Therapeutics, Inc. Common Stock stock for Q4 2019, down 75% quarter-over-quarter.
- 2 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q4 2019 and 11 closed out, a net change of -9 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $162K added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q4 2019 was Adage Capital Partners, an estimated $4.9M sold.
Based on aggregated 13F filings for Q4 2019.